Potential Anti-Inflammatory Effects of the Hydrophilic Fraction of Pomegranate (Punica granatum L.) Seed Oil on Breast Cancer Cell Lines
Abstract
1. Introduction
2. Results and Discussion
2.1. Extraction of Hydrophilic Compounds from Pomegranate Seed Oil
| Polar Extracts From PSO | Yield (%) | TPCmg GAE/100 g oil | DPPH (I%) |
| 8.93 ± 1.02 | 23.07 ± 1.44 | 96.80 ± 8.93 |


2.2. Colorimetric Assay with Sulforhodamine B

2.3. Apoptosis Assay
- Live cells which are not undergoing to apoptosis: annexin V (−) and cells dead marker (−);
- Cells in early apoptosis: annexin V (+) and cells dead marker (−);
- Cells in adavanced apoptosis: annexin V (+) and cells dead marker (+);
- Dead cells which do not cross the apoptotic process (necrosis): annexin V (−) and cells dead marker (+).
| Cells | Live Cells (%) | Cells in Early Apoptosis (%) | Cells in Late Apoptosis (%) | Dead Cells (%) |
|---|---|---|---|---|
| MCF-7 non treated | 95.30 ± 1.02 | 0.95 ± 0.02 | 3.35% ± 1.21% | 0.40 ± 0.04 |
| MCF-7 treated | 92.85 ± 1.15 | 3.50 ± 0.77 | 2.65% ± 0.07% | 1.00 ± 0.09 |
| MDA-MB-231 non treated | 96.79 ± 1.09 | 1.31 ± 0.42 | 1.86% ± 0.54% | 0.05 ± 0.02 |
| MDA-MB-231 treated | 95.75 ± 2.04 | 2.95 ± 0.61 | 1.10% ± 0.05% | 0.20 ± 0.09 |
| Cells | G0/G1 (%) | S (%) | G2/M (%) |
|---|---|---|---|
| MCF-7 Non treated | 5.0 ± 1.2 | 94.2 ± 6.4 | 0.8 ± 0.1 |
| MCF-7 treated | 79.2 ± 5.3 | 7.9 ± 1.6 | 12.9 ± 2.1 |
| MDA-MB-231 non treated | 20.8 ± 3.6 | 18.9 ± 1.2 | 60.3 ± 4.6 |
| MDA-MB-231 treated | 67.5 ± 6.1 | 19.7 ± 2.1 | 12.8 ± 2.3 |
2.4. Cell Cycle Assay
2.5. Evaluation of Cytokine Levels on MDA-MB-231 and MCF-7 Supernatants

2.6. Interactomic Studies

3. Experimental
3.1. Samples and Chemicals
3.2. Oil Extraction
3.3. Extraction and Determination of Total Phenolics
3.4. RP-HPLC-DAD Analysis
3.5. MALDI-TOF MS Analysis
3.6. Antioxidant Activity (DPPH Assay)
3.7. Cell Culture
3.8. Colorimetric Assay with Sulforhodamine B
3.9. Apoptosis Assay
3.10. Cell Cycle Assay
3.11. Bio-Plex Assay
3.12. Bioinformatics Analysis
4. Conclusions
Acknowledgments
Author Contributions
Conflicts of Interest
References
- Wang, Z.; Pan, Z.; Ma, H.; Atungulu, G.G. Extract of phenolics from pomegranate peels. Open Food Sci. J. 2011, 5, 17–25. [Google Scholar] [CrossRef]
- Lansky, E.P.; Newman, R.A. Punica granatum (pomegranate) and its potential for prevention and treatment of inflammation and cancer. J. Ethnopharmacol. 2007, 109, 177–206. [Google Scholar] [CrossRef]
- Rasheed, Z.; Akhtar, N.; Anbazhagan, N.A.; Ramamurthy, S.; Shukla, M.; Haqqi, T.M. Polyphenol-rich pomegranate fruit extract (POMx) suppresses PMACI induced expression of pro-inflammatory cytokines by inhibiting the activation of MAP Kinases and NF-κB in human KU812 cells. J. Inflam. 2009, 6, 1. [Google Scholar] [CrossRef]
- Larrosa, M.; González-Sarrías, A.; García-Conesa, M.T.; Francisco, A.T.B.; Espín, J.C. Urolithins ellagic acid-derived metabolites produced by human colonic microflora exhibit estrogenic and antiestrogenic activities. J. Agric. Food Chem. 2006, 54, 1611–1620. [Google Scholar] [CrossRef]
- Elfalleh, W.; Tlili, N.; Nasri, N.; Yahia, Y.; Hannachi, H.; Chaira, N.; Ying, M.; Ferchichi, A. Antioxidant capacities of phenolic compounds and tocopherols from tunisian pomegranate (Punica granatum) fruits. J. Food Sci. 2011, 76, 707–713. [Google Scholar] [CrossRef]
- Fadavi, A.; Barzegar, M.; Azizi, M.H. Determination of fatty acids and total lipid content in oilseed of 25 pomegranates varieties grown in Iran. J. Food Compos. Anal. 2006, 19, 676–680. [Google Scholar] [CrossRef]
- Kasimsetty, S.G.; Bialonska, D.; Reddy, M.K.; Ma, G.; Khan, S.I.; Ferreira, D. Colon cancer chemopreventive activities of pomegranate ellagitannins and urolithins. J. Agric. Food Chem. 2010, 58, 2180–2187. [Google Scholar] [CrossRef]
- Albrecht, M.; Jiang, W.; Kumi-Diaka, J.; Lansky, E.P.; Gommersall, L.M. Pomegranate extracts potently suppress proliferation Xenograft growth and invasion of human prostate cancer cells. J. Med. Food 2004, 7, 274–283. [Google Scholar]
- Adhami, V.M.; Khan, N.; Mukhtar, H. Cancer chemoprevention by pomegranate: Laboratory and clinical evidence. Nutr. Cancer 2009, 61, 811–815. [Google Scholar] [CrossRef]
- Afaq, F.; Zaid, M.A.; Khan, N.; Dreher, M.; Mukhtar, H. Protective effect of pomegranate-derived products on UVB-mediated damage in human reconstituted skin. Exp. Dermatol. 2009, 18, 553–561. [Google Scholar] [CrossRef]
- Schubert, S.Y.; Lansky, E.P.; Neeman, I. Antioxidant and eicosanoid enzyme inhibition properties of pomegranate seed oil and fermented juice flavonoids. J. Ethnopharmacol. 1999, 66, 11–17. [Google Scholar] [CrossRef]
- Straccia, M.C.; Siano, F.; Coppola, R; la Cara, F.; Volpe, M.G. Extraction and characterization of vegetable oils from cherry seed by different extraction processes. Chem. Eng. Trans. 2012, 27, 391–396. [Google Scholar]
- Kohno, H.; Suzuki, R.; Yasui, Y.; Hosokawa, M.; Miyashita, K.; Tanaka, T. Pomegranate seed oil rich in conjugated linolenic acid suppresses chemically induced colon carcinogenesis in rats. Cancer Sci. 2004, 95, 481–486. [Google Scholar] [CrossRef]
- Arzu, A.B.; Tulay, O.; Lutfiye, Y.E. The Therapeutic Potential of Pomegranate and Its Products for Prevention of Cancer Cancer Prevention-From Mechanisms to Translational Benefits; Tech–Open Access Company: Rijeka, Croatia, 2012; pp. 331–372. [Google Scholar]
- Hora, J.J.; Maydew, E.R.; Lansky, E.P.; Dwivedi, C. Chemopreventive effects of pomegranate seed oil on skin tumor development in CD1 mice. J. Med. Food 2003, 6, 157–161. [Google Scholar] [CrossRef]
- Faria, A.; Calhau, C. The Bioactivity of pomegranate: Impact on health and disease. CRC Crit. Rev. Food Sci. Nutr. 2011, 51, 626–634. [Google Scholar] [CrossRef]
- Caligiani, A; Bonzanini, F.; Palla, G.; Cirlini, M.; Bruni, R. Characterization of a potential nutraceutical ingredient: Pomegranate (Punica granatum L.) seed oil unsaponifiable fraction. Plant. Foods Hum. Nutr. 2010, 65, 277–283. [Google Scholar] [CrossRef]
- Adams, L.S.; Seeram, N.P.; Aggarwal, B.B.; Takada, Y.; Sand, D.; Heber, D. Pomegranate juice total pomegranate ellagitannins and punicalagin suppress inflammatory cell signaling in colon cancer Cells. J. Agric. Food Chem. 2006, 54, 980–985. [Google Scholar]
- Malik, A.; Afaq, F.; Sarfaraz, S.; Adhami, V.M.; Syed, D.N.; Mukhtar, H. Pomegranate fruit Juice for chemoprevention and chemotherapy of prostate cancer. Proc. Natl. Acad. Sci. USA 2005, 2, 14813–14818. [Google Scholar]
- Pande, G.; Akoh, C.C. Antioxidant capacity and lipid characterization of six Georgia-grown pomegranate cultivars. J. Agric. Food Chem. 2009, 57, 9427–9436. [Google Scholar] [CrossRef]
- Jing, P.; Tian, Y.; Shi, H.; Sheng, Y.; Slavin, M.; Gao, B.; Liud, L.; Yu, L. Antioxidant properties and phytochemical composition of China-grown pomegranate seeds. Food Chem. 2012, 132, 1457–1464. [Google Scholar] [CrossRef]
- Turtygin, A.V; Deineka, V.I.; Deineka, L.A. Determination of the triglyceride composition of pomegranate seed oil by reversed-phase HPLC and spectrophotometry. J. Anal. Chem. 2013, 68, 558–563. [Google Scholar]
- Hontecillas, R.; O’Shea, M.; Einerhand, A.; Diguardo, M.; Bassaganya-Riera, J. Activation of PPAR gamma and alpha by punicic acid ameliorates glucose tolerance and suppresses obesity-related inflammation. J. Am. Coll. Nutr. 2009, 28, 184–195. [Google Scholar] [CrossRef]
- Bassaganya-Riera, J.; DiGuardo, M.; Climent, M.; Vives, C.; Carbo, A.; Jouni, Z.E.; Einerhand, A.W.; O’Shea, M.; Hontecillas, R. Activation of PPARγ and δ by dietary punicic acid ameliorates intestinal inflammation in mice. Br. J. Nutr. 2011, 106, 878–886. [Google Scholar] [CrossRef]
- Dehqanzada, Z.A.; Storrer, C.E.; Hueman, M.T.; Foley, R.J.; Harris, K.A.; Jama, Y.H.; Shriver, C.D.; Ponniah, S.; Peoples, G.E. Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology. Oncol. Rep. 2007, 17, 687–694. [Google Scholar]
- Salcedo, R.; Ponce, M.L.; Young, H.A.; Wasserman, K.; Ward, J.M.; Kleinman, H.K.; Oppenheim, J.J.; Murphy, W.J. Human endothelial cells express CCR2 and respond to MCP-1: Direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000, 196, 34–40. [Google Scholar]
- Kolls, J.K.; Linden, A. Interleukin-17 family members and infiammation. Immunity 2004, 21, 467–476. [Google Scholar] [CrossRef]
- Fabregat, I. Dysregulation of apoptosis in hepatocellular carcinoma cells. World J. Gastroenterol. 2009, 15, 513–520. [Google Scholar] [CrossRef]
- Feurino, L.W.; Zhang, Y.; Bharadwaj, U.; Zhang, R.; Li, F.; Fisher, W.E.; Brunicardi, F.C.; Chen, C.; Yao, Q.; Min, L. IL-6 stimulates Th2 type cytokine secretion and upregulates VEGF and NRP-1 expression in pancreatic cancer cells. Cancer Biol. Ther. 2007, 6, 1096–1100. [Google Scholar] [CrossRef]
- Ren, M.; Guo, Q.; Guo, L.; Lenz, M.; Qian, F.; Koenen, R.R.; Xu, H.; Schilling, A.B.; Weber, C.; Ye, R.D.; et al. WJPolymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme. EMBO J. 2010, 129, 3952–3966. [Google Scholar]
- Waldmann, T.A. The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 2006, 6, 595–601. [Google Scholar] [CrossRef]
- Dun, X.; Li, X.Q.; Li, L.; Xu, Y.Y.; Feng, Y.M. The detection of ESR1/PGR/ERBB2 mRNA levels by RT-QPCR: A better approach for subtyping breast cancer and predicting prognosis. Breast Cancer Res. Treat. 2013, 138, 59–67. [Google Scholar] [CrossRef]
- Glynn, S.A.; Boersma, B.J.; Dorsey, T.H.; Yi, M.; Yfantis, H.G.; Ridnour, L.A.; Martin, D.N.; Switzer, C.H.; Hudson, R.S.; Wink, D.A.; et al. Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J. Clin. Invest. 2010, 120, 3843–3854. [Google Scholar] [CrossRef]
- Singleton, V.L.; Rossi, J.A. Colorimetry of total phenolics with phosphomolybdic-phosphotungstic acid reagents. Am. J. Enol. Viticult. 1965, 16, 144–158. [Google Scholar]
- Brand-Williams, W.; Cuvelier, M.E.; Berset, C. Use of free radical method to evaluate antioxidant activity. LWT-Food Sci. Technol. 1995, 28, 25–30. [Google Scholar] [CrossRef]
- Rusolo, F.; Pucci, B.; Colonna, G.; Capone, F.; Guerriero, E.; Milone, M.R.; Nazzaro, M.; Volpe, M.G.; di Bernardo, G.; Castello, G.; et al. Evaluation of selenite effects on selenoproteins and cytokinome in human hepatoma cell lines. Molecules 2013, 18, 2549–2562. [Google Scholar] [CrossRef]
- Sample Availability: Samples of the pomegranate seeds and their extracts are available from the authors.
© 2014 by the authors. licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license ( http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Costantini, S.; Rusolo, F.; De Vito, V.; Moccia, S.; Picariello, G.; Capone, F.; Guerriero, E.; Castello, G.; Volpe, M.G. Potential Anti-Inflammatory Effects of the Hydrophilic Fraction of Pomegranate (Punica granatum L.) Seed Oil on Breast Cancer Cell Lines. Molecules 2014, 19, 8644-8660. https://doi.org/10.3390/molecules19068644
Costantini S, Rusolo F, De Vito V, Moccia S, Picariello G, Capone F, Guerriero E, Castello G, Volpe MG. Potential Anti-Inflammatory Effects of the Hydrophilic Fraction of Pomegranate (Punica granatum L.) Seed Oil on Breast Cancer Cell Lines. Molecules. 2014; 19(6):8644-8660. https://doi.org/10.3390/molecules19068644
Chicago/Turabian StyleCostantini, Susan, Fabiola Rusolo, Valentina De Vito, Stefania Moccia, Gianluca Picariello, Francesca Capone, Eliana Guerriero, Giuseppe Castello, and Maria Grazia Volpe. 2014. "Potential Anti-Inflammatory Effects of the Hydrophilic Fraction of Pomegranate (Punica granatum L.) Seed Oil on Breast Cancer Cell Lines" Molecules 19, no. 6: 8644-8660. https://doi.org/10.3390/molecules19068644
APA StyleCostantini, S., Rusolo, F., De Vito, V., Moccia, S., Picariello, G., Capone, F., Guerriero, E., Castello, G., & Volpe, M. G. (2014). Potential Anti-Inflammatory Effects of the Hydrophilic Fraction of Pomegranate (Punica granatum L.) Seed Oil on Breast Cancer Cell Lines. Molecules, 19(6), 8644-8660. https://doi.org/10.3390/molecules19068644

